Hosted on MSN20h
Cantor Fitzgerald Initiates Coverage of GH Research (GHRS) with Overweight Recommendation
Fintel reports that on February 13, 2025, Cantor Fitzgerald initiated coverage of GH Research (NasdaqGM:GHRS) with a ...
pharmaphorum23h
4DMT gene therapy cuts need for Eylea in wet AMD trial
They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.